高级检索
当前位置: 首页 > 详情页

Traditional Chinese medicine, Fuzheng Kang-Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Laboratory of Tumor Biology and Targeted Therapies of TCM [2]Department of Medical Oncology,Guangdong Provincial Hospital of Chinese Medicine [3]Guangzhou University of Chinese Medicine,Guangzhou, Guangdong 510120, P.R. China
出处:
ISSN:

关键词: Fuzheng Kang-Ai decoction lung cancer STAT3/MMP9 pathway epithelial-mesenchymal transition

摘要:
Lung cancer is a leading cause of cancer-associated mortality worldwide, including in developing countries such as China. Traditional Chinese medicine may provide a novel insight for the treatment of patients with lung cancer. The present study aimed to uncover the mechanism by which the Chinese herbal medicine, Fuzheng Kang-Ai (FZKA), functions on lung cancer cell metastasis. The results demonstrated that treatment with FZKA markedly inhibited cell viability, migration and invasion of lung cancer cells, as determined by cell viability and Transwell assays. Notably, the activity and expression of matrix metalloproteinase 9 (MMP9) was significantly inhibited by FZKA treatment on lung cancer cells, as determined by an MMP9 activity assay and western blot analysis. Furthermore, FZKA markedly inhibited epithelial-mesenchymal transition (EMT) of lung cancer cells by inhibiting the expression of the mesenchymal markers N-cadherin and vimentin. In addition, activation of the oncoprotein signal transducer and activator of transcription 3 (STAT3) was suppressed following treatment with FZKA. Conversely, overexpression of STAT3 was able to rescue MMP9 activity following FZKA treatment. The present study indicated that FZKA may inhibit lung cancer metastasis via the STAT3/ MMP9 pathway and EMT, suggesting that FZKA may serve as a novel promising therapeutic strategy for the treatment of patients with late stage lung cancer.

基金:

基金编号: grant nos. 81273965 and 81272614

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Laboratory of Tumor Biology and Targeted Therapies of TCM [2]Department of Medical Oncology,Guangdong Provincial Hospital of Chinese Medicine [3]Guangzhou University of Chinese Medicine,Guangzhou, Guangdong 510120, P.R. China
共同第一作者:
通讯作者:
通讯机构: [1]Laboratory of Tumor Biology and Targeted Therapies of TCM [2]Department of Medical Oncology,Guangdong Provincial Hospital of Chinese Medicine [*1]Laboratory of Tumor Biology and Targeted Therapies of TCM, Guangdong Provincial Hospital of Chinese Medicine, 55 Inner Ring West Road, Higher Education Mega Center, Guangzhou, Guangdong 510120, P.R. China [*2]Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou, Guangdong 510120, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号